Amgen Will Divest Facility

February 2011
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p89
Trade Publication
The article reports on the agreement signed by Amgen Inc. to sell the rights and all its assets in it Fremont, California development and manufacturing facility to Boehringer Ingelheim Ltd.


Related Articles

  • Amgen Makes History with $762M Off-Label Settlement. Serebrov, Mari // BioWorld Today;12/20/2012, Vol. 23 Issue 246, p1 

    The article reports on the completion of a settlement agreement by biotechnology company Amgen Inc. to resolve federal claims stemming from whistleblower suits alleging off-label marketing of several of its top-selling drugs. Majority of the settlement will be paid to the U.S. government to...

  • Boehringer Ingelheim initiates Phase III lung cancer trial.  // PharmaWatch: Cancer;Sep2009, Vol. 8 Issue 9, p5 

    The article reports on the Phase III of clinical study for lung treatment medicine BIBW 2992 initiated by German pharmaceutical company Boehringer Ingelheim Ltd. in Germany. It highlights that the medicine is an orally administered and irreversible dual inhibitor of epidermal growth factor...

  • Drugs giant reviews £20m media work.  // Campaign;8/7/2009, Issue 31, p2 

    The article reports that the pharmaceuticals company Boehringer Ingelheim Ltd. is reviewing its 20 million pounds global media planning and buying account in Great Britain. It notes that Boehringer has approached major media networks to pitch for its business. It mentions that the company gave...

  • Boehringer Ingelheim wins EU approval for new formulation of Parkinson's drug.  // PharmaWatch: CNS;Dec2009, Vol. 8 Issue 12, p6 

    The article reports on the approval granted by the European Commission (EC) to Boehringer Ingelheim Ltd. on its new formulation of new prolonged-release Mirapexin/Sifrol tablet for the treatment of Parkinson's disease. It states that the approval was based on the clinical trials submitted by the...

  • Boehringer Ingelheim's lead hepatitis C compound moves into Phase III - the first within the BI HCV portfolio.  // Biomedical Market Newsletter;5/21/2011, p506 

    The article reports that Boehringer Ingelheim Ltd. announces the study outline for the pivotal Phase III clinical trials designed to evaluate BI 201335, as treatment for patients with Hepatitis C virus. According to Professor Klaus Dugi, Boehringer is delighted to receive Fast Track designation...

  • AT CLOSING NEWS.  // Agri Marketing;Oct2009, Vol. 47 Issue 8, p8 

    The article offers news briefs related to agricultural business. Boehringer Ingelheim (BI) Ltd. has agreed with Pfizer Inc. to acquire some assets of Wyeth Pharmaceuticals' Fort Dodge Animal Health after the merger of Wyeth and Pfizer. Roger N. Beachy was appointed director of the National...

  • SECTION 18: RESPIRATORY TRACT.  // Monthly Prescribing Reference;Apr2010, Vol. 26 Issue 4, p289 

    The article offers information on several prescriptive medications for respiratory tract infections. It says that the Atrovent HFA from Boehringer Ingelheim Ltd. is used to treat bronchospasm in adults due to chronic bronchitis and emphysema. The Gly-Oxide from GlaxoSmithKline is given as part...

  • Boehringer's Pradaxa Approved by FDA.  // Contract Pharma;Nov/Dec2010, Vol. 12 Issue 9, p92 

    The article offers information on various issues related to drug testing and drug approval of U.S. Food and Drug Administration (FDA). It says that positive results were achieved by Alkermes Inc. for its Phase I study on the investigational combination of buprenorphine and ALKS 33. It states...

  • Amgen Sheds Three Products to Focus on 'Bigger Picture.'. Boggs, Jennifer // BioWorld Today;9/16/2008, Vol. 19 Issue 180, p1 

    The article reports that Amgen has divested three marketed products to Swedish specialty pharmaceutical firm Biovitrum AB for $130 million up front, plus potential sales milestones and royalties. Under terms of the deal, Biovitrum will acquire marketed biologics Kepivance and Stemgen and pick up...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics